Survey: 78% of UK Medical Cannabis Patients Report Improved Quality of Life

A large-scale patient survey conducted across six UK medical cannabis clinics has revealed that 78% of respondents reported a meaningful improvement in quality of life since beginning their treatment — findings that add to a growing body of real-world evidence supporting the therapeutic value of prescribed cannabis in the United Kingdom.

The survey, which gathered responses from over 1,400 patients, assessed outcomes across pain management, sleep quality, anxiety levels, mobility and overall wellbeing. Pain relief and improved sleep were the most commonly cited areas of benefit, each reported by more than 65% of participants.

Opioid Reduction Findings

One of the most clinically significant findings was that 61% of respondents had reduced their use of conventional opioid-based pain medications since starting medical cannabis treatment. This corroborates earlier studies suggesting that cannabis can serve as an effective opioid-sparing therapy, with implications for the NHS opioid prescribing burden and addiction rates.

A smaller but notable proportion — 18% — reported stopping opioid use entirely, attributing the change directly to the effectiveness of their cannabis prescription in managing underlying pain conditions.

Calls for NHS Integration

Survey authors called for the findings to inform NHS England's ongoing review of pain management pathways, arguing that the scale of patient-reported benefit justifies greater integration of medical cannabis into standard care. They also highlighted affordability as a persistent barrier, with many patients spending upwards of £300 per month on private prescriptions.